Adriana Roque

Dr. Adriana Roque


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2022 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
CACarolina Afonso
Carolina Afonso
ARAdriana Roque
Adriana Roque
CACátia Almeida
Cátia Almeida
MPMaria Beatriz Pimentão
Maria Beatriz Pimentão
MJMaria José Julião
Maria José Julião
MGMarília Gomes
Marília Gomes
Iatrogenic immunodeficiency-associated lymphoproliferative disorders (LPDs) are heterogeneous clinicopathological entities developing in patients receiving immunosuppression. Outside the posttransplant setting, methotrexate (MTX), a drug commonly used for the treatment of autoimmune diseases, is an immunosuppressive agent frequently reported to be associated with LPD. MTX-associated LPD (MTX-LPD) includes a spectrum of lymphocytic proliferations, ranging from polyclonal hyperplasia to malignant lymphoma. MTX-LPD diagnosis can be challenging, as signs and symptoms are often nonspecific and may overlap with those of several other conditions, including exacerbation of the underlying autoimmune disease. Spontaneous regression of LPD after MTX discontinuation is characteristic of MTX-LPD, therefore avoiding chemotherapeutic intervention in a significant proportion of patients. Other cases, however, should receive chemotherapy.

17 June 2021 in Hematological Oncology
Verified
Journal Article
Open access
PDF file
DND. S Neves
D. S Neves
SDSara Duarte
Sara Duarte
CAC Afonso
C Afonso
BMB Marques
B Marques
CLC. B Lima
C. B Lima
AEA Espadana
A Espadana
Click on the article title to read more.

3 October 2022 in HemaSphere
Verified
Journal Article
Open access
CACátia Almeida
Cátia Almeida
RSRita Costa E. Sousa
Rita Costa E. Sousa
ARAdriana Roque
Adriana Roque
MAMaria Carolina Afonso
Maria Carolina Afonso
DNDulcelena Neves
Dulcelena Neves
MGMarília Gomes
Marília Gomes

24 August 2026 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
Eirini KatodritouEirini Katodritou
Eirini Katodritou
BFBruna Velosa Ferreira
Bruna Velosa Ferreira
EKEfstathios Kastritis
Efstathios Kastritis
DDDimitra Dalampira
Dimitra Dalampira
ESEmmanouil Spanoudakis
Emmanouil Spanoudakis
Evangelos TerposEvangelos Terpos
Evangelos Terpos

5 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ARAdriana Roque
Adriana Roque
APArtur Paiva
Artur Paiva
RSRaquel Seiça
Raquel Seiça
CGCatarina Geraldes
Catarina Geraldes
Immunotherapy has revolutionized the treatment of multiple myeloma (MM), but durable immune control remains limited, increasing interest in how the bone marrow (BM) microenvironment influences antitumor immunity. BM adipocytes (BMAds) are increasingly recognized as metabolically active components of the BM. This review summarizes the current evidence linking BMAds to myeloma cell survival and immune cell function, particularly T cell activity. It also discusses their potential relevance to monoclonal antibodies, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapy. Preclinical studies have shown that myeloma-associated BMAds undergo lipid depletion and acquire inflammatory and senescence-associated secretory features. BM lipid exposure is associated with impaired CD8+ T-cell metabolic fitness, whereas leptin receptor activation suppresses invariant natural killer T-cell anti-myeloma activity. Evidence concerning conventional natural killer cells and other immune compartments remains limited. Available clinical evidence is predominantly cross-sectional and therefore does not establish a direct role for BMAds in resistance to current immunotherapies or clarify whether they influence therapeutic target availability or function as clinically relevant bystander targets. Patient- and treatment-related factors, including aging and obesity, may further reshape the adipocytic-stromal and immune landscape of the marrow, potentially modifying local responses to immunotherapy. Future studies combining patient-derived multicellular models with spatial and longitudinal approaches should determine how BMAd-associated metabolic, inflammatory, and adipokine signaling affect immune control and treatment outcomes in MM and whether these processes can be therapeutically modulated.

17 June 2021 in Hematological Oncology
Verified
Journal Article
Open access
PDF file
CAC. Afonso
C. Afonso
SDSara Duarte
Sara Duarte
BMB. Marques
B. Marques
CLC. Barros Lima
C. Barros Lima
DND. Neves
D. Neves
AEA. I. Espadana
A. I. Espadana
Click on the article title to read more.